Companies / BIIB vs MRNA
BIIB vs MRNA: Biogen and Moderna
Biogen (BIIB) reported $9.9B in revenue against a 13.1% net margin, while Moderna (MRNA) reported $1.9B at a -145.2% net margin, most recently.
| Metric | BIIB | MRNA |
|---|---|---|
| Revenue | $9.9B | $1.9B |
| Net Income | $1.3B | $-2.8B |
| Gross Margin | 75.7% | 55.3% |
| Operating Margin | 15.7% | -158.1% |
| EPS (Diluted) | $8.79 | $-7.26 |
| Free Cash Flow | $2.1B | $-2.1B |
| Total Debt | $6.3B | $0.6B |
| P/E Ratio | 20.0× | n/m |
| P/B Ratio | n/m | 1.3× |
| Stock Price | $244.12 | $241.26 |
Free: last 5 years
| Fiscal year | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| BIIB Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | $11.0B | $10.2B | $9.8B | $9.7B | $9.9B |
| MRNA Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | $18.5B | $19.3B | $6.8B | $3.2B | $1.9B |